Lone Star Bio

Found 16,863 articles

• 

  BioSpace Launches 2022 Hotbed Maps to Highlight Thriving Life Sciences Clusters

  1/18/2022

  As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.

• Actuate Therapeutics Congratulates Dr. Patricia LoRusso on Being Named AACR President-Elect

  3/23/2023

  Actuate Therapeutics, Inc. today announced that Patricia M. LoRusso, DO, PhD (hc), a member of its Scientific Advisory Board has been Elected as President-Elect the American Association of Cancer Research for 2023-2024.

• Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene Therapies

  3/23/2023

  Rodney Varner , CEO of Genprex, Inc. today commended The U.S. Food and Drug Administration's (FDA) initiative that aims to expedite the development of gene therapies for patients with rare diseases.

• Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination

  3/23/2023

  Graf Acquisition Corp. IV and NKGen Biotech, Inc. announced that they have signed a non-binding letter of intent to pursue a business combination.

• Moleculin Reports Full Year 2022 Financial Results and Provides Pipeline Update

  3/23/2023

  Moleculin Biotech, Inc. today reported its financial results for the fiscal year ended December 31, 2022 and provided a pipeline update.

• DM Clinical Research Seeks Children & Adolescents for COVID-19, RSV, Lyme Disease and Migraine Studies

  3/23/2023

  Houston-based DM Clinical Research, a national network of clinical trial sites, is seeking parents willing to enroll children and adolescents in pediatric studies focused on COVID-19, Lyme disease, migraine headaches and respiratory syncytial virus (RSV).

• Coya Therapeutics, Inc. to Present at the Virtual Investor Summit on Wednesday, March 29, 2023, at 11:00am ET

  3/23/2023

  Coya Therapeutics, Inc. today announced management will present at the Virtual Investor Summit on Wednesday, March 29, 2023 at 11:00am ET.

• Mangoceuticals, Inc. Announces Closing of $5 Million Initial Public Offering

  3/23/2023

  Mangoceuticals, Inc. ("MangoRx" or the "Company") (NASDAQ:MGRX), a company focused on developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded "Mango," today announced the closing of its initial public offering of 1,250,000 shares of common stock at a public offering price of $4.00 per share.

• Actuate Therapeutics Congratulates Dr. Patricia LoRusso on Being Named AACR President-Elect

  3/23/2023

  Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced that Patricia M. LoRusso, DO, PhD (hc), a member of its Scientific Advisory Board, has been elected as President-Elect of the American Association of Cancer Research for 2023-2024.

• Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

  3/22/2023

  Marker Therapeutics, Inc. today reported fiscal year 2022 financial results and provided updates for its clinical development programs.

• Moleculin Announces Interim Phase 2 Data in STS Clinical Trial and Update on Recruiting, Preliminary Efficacy and Expected Milestones for AML Clinical Trials

  3/22/2023

  Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company) today announced recent activity, new positive data and expected near term milestones across its clinical development pipeline.

• Galderma launches FACE by Galderma™, a cutting-edge aesthetic visualization tool that simulates injectable treatment results in real-time

  3/22/2023

  Galderma announced today the launch of FACE by Galderma™, an innovative aesthetic visualization tool powered by augmented reality (AR) that allows aesthetic professionals and patients to visualize injectable treatment results* at the planning stage before treatment begins.

• Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal MetastasesFirst data readout of Phase 1/Part A trial expected second half of 2023

  3/22/2023

  Plus Therapeutics, Inc. today announced treatment of the first patient in Cohort 3 of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of rhenium ( 186 Re) obisbemeda for the treatment of leptomeningeal metastases (LM) from solid tumors.

• New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma

  3/22/2023

  Natera, Inc. (NASDAQ: NTRA) today announced a new study published in Cancer showing the prognostic and predictive utility of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera.

• Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)

  3/21/2023

  Coya Therapeutics, Inc. today reported 48-week clinical data for its proof-of-concept open-label study in 4 ALS patients indicating that treatment with COYA 302 appeared to ameliorate disease progression.

• Proxima Clinical Research Launches Early Phase Oncology Network for New Investigational Therapies

  3/21/2023

  Proxima Clinical Research ("Proxima CRO") announced today it is expanding its early phase oncology clinical trials offering with its Early Phase Oncology Network, a group of oncology-specific scientific experts and early phase clinical trials clinics that allows for quick and easy site enrollment and expert insight, feedback, and guidance in first-in-human Phase I and Phase II clinical oncology trials.

• Direct Biologics Announces Initiation of Phase 1 Clinical Trial for Medically Refractory Crohn’s Disease

  3/21/2023

  Direct Biologics, LLC announced it has dosed the first patient in its Phase 1 clinical trial evaluating ExoFlo ™ for the treatment of patients with medically refractory Crohn’s disease.

• Immatics Announces Full Year 2022 Financial Results and Corporate Update

  3/21/2023

  Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter and full year ended December 31, 2022.

• Mangoceuticals, Inc. Announces Pricing of Initial Public Offering

  3/21/2023

  Mangoceuticals, Inc. ("MangoRx" or the "Company") today announced the pricing of its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share for a total of $5,000,000 of gross proceeds to the Company, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

• Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars

  3/21/2023

  Lantern Pharma Inc. announced that Lantern management and employees will be presenting at three upcoming events: Rare Disease Innovation & Partnership Summit in Philadelphia, PA on Wednesday, March 22 at 5:00 p.m. ET.